Molecular Partners (MOLN.SW) Stock Price

Molecular Partners Price

SIX·CLOSED
3.24CHF-0.0100 (-0.31 %)
Market closed

Revenue at Molecular Partners has contracted by 15.7% per year over the past 11 years to 4.97 M CHF. For Molecular Partners, the net margin of -1,087.4% is down versus -671.7% a few years ago. The consensus 12-month price target for Molecular Partners is 8.16 CHF, about 151.9% above where the stock trades today. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 17% above its 52-week low.

Molecular Partners stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Molecular Partners over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Molecular Partners stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Molecular Partners's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Molecular Partners Stock Price History
DateMolecular Partners Price
8/7/20263.24 CHF
8/6/20263.25 CHF
8/5/20263.28 CHF
8/4/20263.29 CHF
7/31/20263.33 CHF
7/30/20263.26 CHF
7/29/20263.25 CHF
7/28/20263.18 CHF
7/27/20263.24 CHF
7/24/20263.18 CHF
7/23/20263.17 CHF
7/22/20263.25 CHF
7/21/20263.20 CHF
7/20/20263.17 CHF
7/17/20263.23 CHF
7/16/20263.24 CHF
7/15/20263.25 CHF
7/14/20263.16 CHF
7/13/20263.16 CHF
7/10/20263.23 CHF
7/9/20263.21 CHF
7/8/20263.24 CHF
7/7/20263.20 CHF
7/6/20263.20 CHF
7/3/20263.10 CHF
7/2/20263.20 CHF
7/1/20263.10 CHF
6/30/20263.13 CHF
6/29/20263.18 CHF
6/26/20263.18 CHF
6/25/20263.18 CHF
6/24/20263.12 CHF
6/23/20263.10 CHF
6/22/20263.04 CHF
6/19/20263.09 CHF
6/18/20263.12 CHF
6/17/20263.13 CHF
6/16/20263.15 CHF
6/15/20263.03 CHF
6/12/20263.03 CHF
6/11/20263.02 CHF
6/10/20263.08 CHF
6/9/20263.05 CHF
6/8/20263.14 CHF
6/5/20263.00 CHF
6/4/20263.04 CHF
6/3/20263.12 CHF
6/2/20263.00 CHF
6/1/20263.17 CHF
5/29/20263.14 CHF
5/28/20263.08 CHF
5/27/20263.15 CHF
5/26/20263.08 CHF
5/22/20263.15 CHF
5/21/20262.88 CHF
5/20/20262.92 CHF
5/19/20262.86 CHF
5/18/20262.91 CHF
5/15/20262.97 CHF
5/13/20263.01 CHF
5/12/20263.14 CHF
5/11/20263.18 CHF
5/8/20263.23 CHF
5/7/20263.24 CHF
5/6/20263.28 CHF
5/5/20263.37 CHF
5/4/20263.31 CHF
4/30/20263.21 CHF
4/29/20263.36 CHF
4/28/20263.34 CHF
4/27/20263.35 CHF
4/24/20263.27 CHF
4/23/20263.37 CHF
4/22/20263.43 CHF
4/21/20263.46 CHF
4/20/20263.50 CHF
4/17/20263.27 CHF
4/16/20263.26 CHF
4/15/20263.30 CHF
4/14/20263.21 CHF
4/13/20263.17 CHF
4/10/20263.38 CHF
4/9/20263.40 CHF
4/8/20263.34 CHF
4/7/20263.15 CHF
4/2/20263.03 CHF
3/27/20263.25 CHF
3/26/20263.32 CHF
3/25/20263.36 CHF
3/24/20263.32 CHF
3/23/20263.38 CHF
3/20/20263.47 CHF
3/19/20263.52 CHF
3/17/20263.19 CHF
3/16/20263.32 CHF
3/13/20263.45 CHF
3/12/20263.77 CHF
3/11/20263.75 CHF
3/10/20263.69 CHF
3/9/20263.86 CHF
3/6/20263.89 CHF
3/5/20263.95 CHF
2/26/20263.85 CHF
2/25/20263.93 CHF
2/24/20263.90 CHF
2/23/20263.77 CHF
2/20/20263.70 CHF
2/19/20263.75 CHF
2/18/20263.62 CHF
2/17/20263.66 CHF
2/16/20263.51 CHF
2/13/20263.41 CHF
2/12/20263.54 CHF
2/11/20263.53 CHF
2/10/20263.58 CHF
2/9/20263.63 CHF
2/6/20263.60 CHF
2/5/20263.54 CHF
2/4/20263.52 CHF
2/3/20263.65 CHF
2/2/20263.47 CHF
1/30/20263.26 CHF
1/29/20263.23 CHF
1/28/20263.07 CHF
1/27/20263.13 CHF
1/26/20263.10 CHF
1/23/20263.11 CHF
1/22/20263.13 CHF
1/21/20263.15 CHF
1/20/20263.16 CHF
1/19/20263.17 CHF
1/16/20263.28 CHF
1/15/20263.28 CHF
1/14/20263.31 CHF
1/13/20263.33 CHF
1/12/20263.36 CHF
1/9/20263.27 CHF
1/8/20263.40 CHF
1/7/20263.39 CHF
1/6/20263.49 CHF
1/5/20263.42 CHF
12/30/20253.36 CHF
12/29/20253.40 CHF
12/23/20253.51 CHF
12/22/20253.53 CHF
12/19/20253.38 CHF
12/18/20253.36 CHF
12/17/20253.40 CHF
12/16/20253.31 CHF
12/15/20253.32 CHF
12/12/20253.36 CHF
12/11/20253.47 CHF
12/10/20253.32 CHF
12/9/20253.22 CHF
12/8/20253.53 CHF
12/5/20253.37 CHF
12/4/20253.43 CHF
12/3/20253.32 CHF
12/2/20253.37 CHF
12/1/20253.22 CHF
11/28/20253.18 CHF
11/27/20253.14 CHF
11/26/20253.22 CHF
11/25/20253.22 CHF
11/24/20253.17 CHF
11/21/20253.10 CHF
11/20/20253.33 CHF
11/19/20253.33 CHF
11/18/20253.30 CHF
11/17/20253.33 CHF
11/14/20253.34 CHF
11/13/20253.55 CHF
11/12/20253.29 CHF
11/11/20253.08 CHF
11/10/20253.23 CHF
11/7/20253.26 CHF
11/6/20253.59 CHF
11/5/20253.42 CHF
11/4/20253.36 CHF
11/3/20253.12 CHF
10/31/20253.01 CHF
10/30/20252.98 CHF
10/29/20252.95 CHF
10/28/20252.93 CHF
10/27/20252.85 CHF
10/24/20252.80 CHF
10/23/20252.79 CHF
10/22/20252.84 CHF
10/21/20252.86 CHF
10/20/20252.87 CHF
10/17/20252.84 CHF
10/16/20252.88 CHF
10/15/20252.92 CHF
10/14/20252.93 CHF
10/13/20252.96 CHF
10/10/20252.95 CHF
10/9/20252.98 CHF
10/8/20252.91 CHF
10/7/20252.98 CHF
10/6/20252.86 CHF
10/3/20252.88 CHF
10/2/20252.90 CHF
10/1/20252.84 CHF
9/30/20252.88 CHF
9/29/20252.88 CHF
9/26/20252.80 CHF
9/25/20252.88 CHF
9/24/20252.85 CHF
9/23/20252.81 CHF
9/22/20252.78 CHF
9/19/20252.84 CHF
9/18/20252.78 CHF
9/17/20252.79 CHF
9/16/20252.83 CHF
9/15/20252.83 CHF
9/12/20252.84 CHF
9/11/20252.82 CHF
9/10/20252.80 CHF
9/9/20252.80 CHF
9/8/20252.82 CHF
9/5/20252.84 CHF
9/4/20252.87 CHF
9/3/20252.82 CHF
9/2/20252.86 CHF
9/1/20252.90 CHF
8/29/20252.90 CHF
8/28/20253.01 CHF
8/27/20252.98 CHF
8/26/20252.96 CHF
8/25/20252.93 CHF
8/22/20252.97 CHF
8/21/20252.90 CHF
8/20/20252.86 CHF
8/19/20252.91 CHF
8/18/20252.86 CHF
8/15/20252.87 CHF
8/14/20252.88 CHF
8/13/20252.90 CHF
8/12/20253.02 CHF
8/11/20252.95 CHF
Access this data via the Eulerpool API
Get Free API Key

Molecular Partners Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
7.04 M CHF
-61.11 M CHF
-61.98 M CHF
Jan 1, 2024
4.97 M CHF
-61.22 M CHF
-54.04 M CHF
Jan 1, 2025
0.00 CHF
-55.44 M CHF
-61.65 M CHF
Jan 1, 2026 (e)
11.00 M CHF
-3.05 M CHF
-48.84 M CHF
Jan 1, 2027 (e)
61.50 M CHF
-17.03 M CHF
-44.16 M CHF
Jan 1, 2028 (e)
1.25 M CHF
-346,202.00 CHF
-51.05 M CHF
Jan 1, 2029 (e)
33.55 M CHF
-9.29 M CHF
-49.35 M CHF
Jan 1, 2030 (e)
179.20 M CHF
-49.63 M CHF
3.40 M CHF

Molecular Partners Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 10, 2026, 6:50 PM
 
REVENUEM CHF
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CHF
EBITM CHF
EBIT MARGIN%
NET INCOMEM CHF
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
29.0023.0020.0010.0020.009.009.00189.007.004.00–11.0061.001.0033.00179.00
11.54-20.69-13.04-50.00100.00-55.00–2,000.00-96.30-42.86––454.55-98.363,200.00442.42
93.1034.7810.00-50.00-115.00-511.11-511.1173.02-571.43-1,050.00–-18.18-3.28-200.00-6.06-1.12
27.008.002.00-5.00-23.00-46.00-46.00138.00-40.00-42.00-2.00-2.00-2.00-2.00-2.00-2.00
-2.00-19.00-25.00-37.00-36.00-58.00-63.00116.00-61.00-61.00-55.00-3.00-17.00–-9.00-49.00
-6.90-82.61-125.00-370.00-180.00-644.44-700.0061.38-871.43-1,525.00–-27.27-27.87–-27.27-27.37
–-18.00-25.00-37.00-36.00-62.00-63.00117.00-61.00-54.00-61.00-48.00-44.00-51.00-49.003.00
––38.8948.00-2.7072.221.61-285.71-152.14-11.4812.96-21.31-8.3315.91-3.92-106.12
21.9120.8920.9621.2221.5025.0023.6136.0432.8536.8637.4137.4137.4137.4137.4137.41
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Molecular Partners generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Molecular Partners retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Molecular Partners's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Molecular Partners has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Molecular Partners's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Molecular Partners stock margins

The Molecular Partners margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Molecular Partners. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Molecular Partners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-497.19 %
-678.74 %
-683.65 %
Jan 1, 2022
73.23 %
61.52 %
62.17 %
Jan 1, 2023
-579.80 %
-868.26 %
-880.70 %
Jan 1, 2024
-855.81 %
-1,231.73 %
-1,087.38 %
Jan 1, 2025
-855.81 %
- %
- %
Jan 1, 2026 (e)
-855.81 %
-27.70 %
-443.97 %
Jan 1, 2027 (e)
-855.81 %
-27.70 %
-71.80 %
Jan 1, 2028 (e)
-855.81 %
-27.70 %
-4,083.90 %

Molecular Partners Stock Revenue, EBIT, Earnings per Share

The Molecular Partners earnings per share therefore indicates how much revenue Molecular Partners has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.40 CHF
-2.68 CHF
-2.70 CHF
Jan 1, 2022
5.26 CHF
3.24 CHF
3.27 CHF
Jan 1, 2023
0.21 CHF
-1.86 CHF
-1.89 CHF
Jan 1, 2024
0.13 CHF
-1.66 CHF
-1.47 CHF
Jan 1, 2025
0.00 CHF
-1.48 CHF
-1.65 CHF
Jan 1, 2026 (e)
0.32 CHF
-0.08 CHF
-1.44 CHF
Jan 1, 2027 (e)
1.81 CHF
-0.46 CHF
-1.30 CHF
Jan 1, 2028 (e)
0.04 CHF
-0.01 CHF
-1.50 CHF

Molecular Partners business model & stock analysis

Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years.

Molecular Partners SWOT Analysis

Strengths

Molecular Partners AG has several key strengths that contribute to its success and competitive edge. Firstly, the company has a strong and experienced management team with deep industry expertise. This ensures effective decision-making and strategic planning. Secondly, Molecular Partners AG has a diverse and innovative product portfolio, with a focus on developing novel protein therapies. This allows the company to cater to different medical needs and target a wide range of diseases. Lastly, the company has established strong partnerships with leading pharmaceutical companies, which enables it to access additional resources, expertise, and distribution channels.

Weaknesses

Despite its strengths, Molecular Partners AG also faces certain weaknesses that may hinder its growth and market position. One major weakness is the company's dependency on a limited number of product candidates. This increases its vulnerability to potential failures or setbacks in the development process. Additionally, the company may lack sufficient financial resources to independently fund its research and development activities, forcing it to rely heavily on partnerships and funding agreements. Moreover, Molecular Partners AG operates in a highly competitive industry, which could pose challenges in terms of market share and pricing.

Opportunities

There are several opportunities that Molecular Partners AG can explore to drive its growth and expand its market presence. Firstly, the increasing global demand for innovative and effective therapies provides a favorable market environment for the company to introduce and commercialize its product candidates. Secondly, the growing prevalence of various diseases, such as cancer and autoimmune disorders, offers opportunities to target unmet medical needs. Molecular Partners AG can leverage its expertise in protein therapies to develop breakthrough treatments for these conditions. Additionally, expanding into new geographic markets and collaborating with emerging biopharmaceutical companies can broaden the company's customer base and diversify its revenue streams.

Threats

Molecular Partners AG operates in an industry that is subject to various threats that may impact its business operations and profitability. Firstly, regulatory uncertainties and changing compliance requirements pose risks to the company's product development and commercialization efforts. Non-compliance or delays in obtaining necessary approvals could result in significant setbacks and increased costs. Secondly, intellectual property infringement or challenges from competitors could jeopardize Molecular Partners AG's ability to protect its proprietary technologies and product candidates. In addition, fluctuations in currency exchange rates and economic uncertainties may affect the company's financial performance, especially if it relies on international markets.

Molecular Partners Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Molecular Partners historical P/E ratio, EBIT multiple, and P/S ratio

Molecular Partners annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Molecular Partners shares outstanding

The number of shares of Molecular Partners was 37.41 M in 2025. This indicates how many shares Molecular Partners is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
23.61 M Stocks
Jan 1, 2022
36.04 M Stocks
Jan 1, 2023
32.85 M Stocks
Jan 1, 2024
36.86 M Stocks
Jan 1, 2025
37.41 M Stocks
Jan 1, 2026 (e)
37.41 M Stocks
Jan 1, 2027 (e)
37.41 M Stocks
Jan 1, 2028 (e)
37.41 M Stocks

Current Molecular Partners forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (8)
Hold
20.00 % (2)
Sell
0.00 % (0)
12M Price Target
8.16
Last Price
3.24
Currency
CHF
12M Return Potential
151.85 %
LTM Return
0 %

Molecular Partners Analyst Rating Actions

DateFirmActionRating
8/29/2022
SVB Leerink
SVB Leerink
DowngradeOutperformPerform
8/28/2022
SVB Leerink
SVB Leerink
DowngradeOutperformMarket Perform
5/24/2022
Credit Suisse
Credit Suisse
UpgradeUnderperformNeutral
4/26/2022
SVB Leerink
SVB Leerink
MaintainedOutperform
1/13/2022
SVB Leerink
SVB Leerink
MaintainedOutperform
8/26/2021
SVB Leerink
SVB Leerink
MaintainedOutperform

Molecular Partners Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
3/13/2023-0.61CHF-2.03 MCHF-2022 Q4
8/25/2022-0.61CHF-2.03 MCHF-2022 Q2
4/1/2022-0.58CHF-2.03 MCHF-2021 Q4
10/28/2021-0.56CHF-2.03 MCHF-2021 Q3

EESG©

Eulerpool ESG Scorecard© for the Molecular Partners stock

74/100
79
Environment
99
Social
43
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Molecular Partners shareholder structure

% Name
5.95585%
UBS Asset Management (Switzerland)
UBS Asset Management (Switzerland)
2.98776%
GAM Investment Management (Switzerland) AG
GAM Investment Management (Switzerland) AG
1.74407%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
0.99998%
Zürcher Kantonalbank (Asset Management)
Zürcher Kantonalbank (Asset Management)
0.78182%
UBS Asset Management Switzerland AG
UBS Asset Management Switzerland AG
0.76794%
Union Bancaire Privée, UBP SA
Union Bancaire Privée, UBP SA

Molecular Partners Beneficial Ownership Filings (SEC 13D/G)

Free Float
82.9%
Float Shares
-
Shares Outstanding
-

Molecular Partners Executives and Management Board

14 members · avg. age 58 · 14 % women

PA

Dr. Patrick Amstutz (49)

Chief Executive Officer, Executive Director, Member of the Management Board · since 2006

1.10 M CHF

Management

AZ

Mr. Alexander Zuercher (49)

Chief Operating Officer, Member of the Management Board

–
RG

Ms. Renate Gloggner (54)

Executive Vice President - People and Community, Member of the Management Board

–
MS

Dr. Michael Stumpp (52)

Executive Vice President - Projects, Member of the Management Board

–
MS

Mr. Martin Steegmaier

Chief Scientific Officer

–
PL

Dr. Philippe Legenne (59)

Chief Medical Officer

–
SL

Mr. Seth Lewis

Senior Vice President - Investor Relations and Strategy · since 2024

–

Board of Directors

WB

Mr. William Burns (78)

Non-Executive Independent Chairman of the Board

295,000.00 CHF
DH

Dr. Dominik Hoechli (57)

Non-Executive Independent Director

135,000.00 CHF
SH

Mr. Steven Holtzman (71)

Non-Executive Independent Director

135,000.00 CHF
MV

Dr. Michael Vasconcelles (61)

Non-Executive Independent Director

135,000.00 CHF
AF

Dr. Agnete Fredriksen (47)

Non-Executive Independent Director

133,000.00 CHF
SK

Mr. Sandip Kapadia (55)

Non-Executive Independent Director

130,000.00 CHF

Frequently asked questions about Molecular Partners

The business model of Molecular Partners AG revolves around its innovative biotechnology platform, DARPin®. This platform enables the development of differentiated therapeutic candidates, leveraging the targeted nature and multi-specificity of DARPins®. By pioneering the development of DARPins®, Molecular Partners AG aims to address unmet medical needs and create value for patients, physicians, and partners. Through collaborations, licensing agreements, and partnerships, the company seeks to advance its drug candidates across various therapeutic areas, including oncology, ophthalmology, and immunology. Molecular Partners AG's business model focuses on harnessing the potential of DARPins® to deliver effective and precise treatment options for patients worldwide.

Molecular Partners AG is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Molecular Partners AG in the market are large biopharmaceutical companies such as Roche Holding AG, Novartis AG, and Pfizer Inc. These companies also focus on developing innovative biologic therapies and have a broader range of resources and expertise. However, Molecular Partners AG distinguishes itself by its novel DARPin technology, which provides advantages in terms of specificity, safety, and ease of manufacturing. This unique technology sets Molecular Partners AG apart from its competitors and positions it as a leading player in the biopharmaceutical industry.

Molecular Partners AG is a Swiss biotechnology company specializing in the development of innovative therapeutic proteins known as DARPin®s. It was established in 2004 by Christian Zahnd, Michael Stumpp, and Andreas Plückthun. Molecular Partners has a strong scientific foundation in protein engineering and has collaborated with leading pharmaceutical companies globally. The company's DARPin® platform offers advantages over conventional therapeutic approaches, including high specificity, low immunogenicity, and extended half-life. Molecular Partners has a diverse pipeline targeting multiple diseases, including oncology, ophthalmology, and infectious diseases. With a commitment to advancing patient care, Molecular Partners AG continues to leverage its expertise in protein engineering to develop innovative therapies that address unmet medical needs.

Molecular Partners AG has achieved several significant milestones in its journey. The company has successfully advanced its proprietary DARPin platform, leading to strategic partnerships with renowned pharmaceutical companies. With a focus on developing innovative therapeutics, Molecular Partners has witnessed notable achievements, including the initiation of clinical trials for its lead oncology asset, MP0250. The company has also made progress in its ophthalmology pipeline, with the start of clinical studies for its candidate, abicipar. Additionally, Molecular Partners has gained global recognition through collaborations with key industry players, establishing a solid foundation for its continued growth and success.

Molecular Partners AG, a leading biotechnology company, is primarily present in several countries and regions worldwide. The company has a prominent presence in Switzerland, as it is based in Zurich. Additionally, Molecular Partners AG has established a strong foothold in Europe, including the European Union member states. Its global presence extends to the United States, with activities and collaborations in the biotech hub of Boston. With an expanding network and growing collaborations, Molecular Partners AG is well-positioned to serve and operate in various countries and regions, enabling it to contribute to the advancement of innovative biopharmaceutical solutions.

Molecular Partners AG represents a strong focus on innovation, collaboration, and scientific excellence. The company is dedicated to the development of innovative therapies based on its proprietary DARPin platform. With a commitment to addressing unmet medical needs, Molecular Partners AG strives to partner with leading pharmaceutical companies and advance the discovery and development of novel treatments. The company's corporate philosophy emphasizes a patient-centric approach, aiming to improve the lives of individuals by delivering transformative therapies. By harnessing the power of protein engineering, Molecular Partners AG aims to create breakthrough medicines and make a positive impact on healthcare.

Analysts currently set an average price target of 9.52 CHF for the Molecular Partners stock (median: 8.16 CHF), implying +193.8 % versus the latest price. The consensus is based on 10 analyst ratings.

Molecular Partners Analyst Price Targets 2026

10 analysts currently rate the Molecular Partners stock: 8 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Molecular Partners to generate revenue of 11.00 M CHF and earnings per share of -1.31 CHF.

Molecular Partners Analyst Price Targets 2026

Converted at the current exchange rate, the Molecular Partners share trades at 3.47 EUR (3.24 CHF).

The Molecular Partners share (MOLN.SW) is listed on 6 stock exchanges, including: Frankfurt (6ML.F), München (6ML.MU), London (0QXX.L), London (0QXX.L), SIX (Zürich) (MOLN.SW).

Molecular Partners AG is a biotech company specializing in the development of therapeutics with multi-specificity. The company was founded in 2004 and is headquartered in Zurich, Switzerland. The business model of Molecular Partners is based on the development of innovative therapeutics based on the DARPin technology (Designed Ankyrin Repeat Proteins). These are artificially produced proteins that specifically bind to certain target structures in tumor cells or inflammation sites. By using multi-specificity, Molecular Partners' therapeutics are able to address multiple targets simultaneously, leading to improved efficacy and safety. Molecular Partners' portfolio currently includes several drug candidates in various stages of development. The main candidate is MP0250, a multi-specific antibody conjugate (SMAC) for the treatment of solid tumors. MP0250 is currently in Phase II clinical trials and has the potential to become a new standard therapy in oncology. Another important candidate is MP0274, a multi-specific antibody conjugate for the treatment of neovascular eye diseases such as wet AMD. Preliminary results indicate that MP0274 has better efficacy and longer duration of action than the current standard of treatment. In addition, Molecular Partners has partnerships with various pharmaceutical companies, including Amgen, Novartis, and Allergan, to develop innovative therapeutics together. Molecular Partners also collaborates with the biotech company AGC Biologics to improve its production technologies and bring its drug candidates to the market faster and more efficiently. Furthermore, the company also offers services in the field of protein design. It provides its customers with the opportunity to create and produce custom proteins based on the DARPin technology. These services are tailored to the biotech and pharmaceutical sectors and have the potential to generate significant scientific advances and product pipeline developments in national and international customer programs. Molecular Partners' business model is focused on close collaboration with its customers, partners, and stakeholders. The company relies on a stringent, science-based, and agile development strategy aimed at identifying and validating promising drug candidates. In this way, Molecular Partners aims to maintain and expand a strong position in the biotech market in the long term. In summary, Molecular Partners AG is an innovative biopharmaceutical company that has a strong focus on the development of multi-specific antibody conjugates (SMAC). The company relies on a stringent, science-based, and agile development strategy to bring its drug candidates to the market quickly and efficiently. Through collaboration with partners and customers in the national and international arena, as well as the provision of custom proteins, the company aims to sustainably strengthen its position in the biotech industry.

The expected revenue of Molecular Partners is 11.00 M CHF. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Molecular Partners is -48.84 M CHF. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Molecular Partners is currently -2.48. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Molecular Partners stock.

The price-to-sales ratio (P/S) of Molecular Partners is currently 11.02. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Molecular Partners stock.

The Eulerpool Quality Score for Molecular Partners is 1/10.

The ISIN of Molecular Partners is CH0256379097. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Molecular Partners is A12DEH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Molecular Partners is MOLN.SW. The ticker symbol is used to trade Molecular Partners shares on the stock exchange.

Molecular Partners paid dividends every year for the past 0 years.

Molecular Partners is assigned to the 'Health' sector.

The dividends of Molecular Partners are distributed in CHF.

All fundamentals and in-depth analysis of Molecular Partners

Our stock analysis for Molecular Partners stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Partners. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Molecular Partners Stock
Molecular Partners Revenue→
Molecular Partners Stock
Molecular Partners Net Income→
Molecular Partners Stock
Molecular Partners P/E→
Molecular Partners Stock
Molecular Partners P/S→
Molecular Partners Stock
Molecular Partners EBIT→
Molecular Partners Stock
Molecular Partners Dividend→
Molecular Partners Stock
Molecular Partners Directors Dealings→
Molecular Partners Stock
Molecular Partners Stocks→
Molecular Partners Stock
Molecular Partners Market capitalization→
Molecular Partners Stock
Molecular Partners Debt→
Molecular Partners Stock
Molecular Partners Liabilities→
Molecular Partners Stock
Molecular Partners Equity→
Molecular Partners Stock
Molecular Partners AAQS→
Molecular Partners Stock
Molecular Partners Employees→
Molecular Partners Stock
Molecular Partners ROE→
Molecular Partners Stock
Molecular Partners ROA→
Molecular Partners Stock
Molecular Partners ROCE→
Molecular Partners Stock
Molecular Partners News→
Molecular Partners Stock
Molecular Partners Analyst Price Targets→

Health Stocks

Molecular Partners AG ADRMohini Health & HygieneMolecule HoldingsModus Therapeutics HoldingMoleculin BiotechModulight OyjMolecureModernaMolina HealthcareModern Mobility AidsMonash IVF GroupModern Dental GroupAll Stocks A–Z →